President Trump's treatment during his brief hospitalization with coronavirus-related symptoms is quite similar to that of an average patient in Northeast Ohio with one notable difference - the experimental antibody cocktail from Regeneron.
In-Depth: One facet of Trump's treatment not available to the public, still in clinical trials
Credit: WEWS NewsChannel5
Duration: 03:05s
0 shares
3 views
Advertisement
Related news coverage
7pm-2021-01-14
WDEF CBS Chattanooga, TN
5am-2021-01-15
WDEF CBS Chattanooga, TN
You might like
More coverage
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
Accesswire
*PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / *MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX &..
-
NA Proactive news snapshot: InnoCan Pharma Corporation, Mountain Valley MD, Zinc8 Energy Solutions, Alpine 4 Technologies UPDATE ...
Proactive Investors
-
NA Proactive news snapshot: Mountain Valley MD, Zinc8 Energy Solutions, Alpine 4 Technologies, Blackrock Gold, PlantX Life, Marrone Bio, Mandalay Resources UPDATE...
Proactive Investors
-
Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute of Texas
GlobeNewswire
-
Roche confirms US government agreement to purchase additional doses of Regeneron’s casirivimab and imdevimab
GlobeNewswire